Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Griseofulvin
Drug ID BADD_D01042
Description An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Indications and Usage For the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by Trichophyton or Microsporum fungi.
Marketing Status approved; investigational; vet_approved
ATC Code D01AA08; D01BA01
DrugBank ID DB00400
KEGG ID D00209
MeSH ID D006118
PubChem ID 441140
TTD Drug ID D0C1SF
NDC Product Code 0781-5514; 23155-865; 60264-310; 0472-0013; 42794-012; 62135-494; 64980-184; 0713-0850; 49452-3363; 23155-864; 62135-496; 64980-185; 62135-495; 64980-186; 71052-109; 0781-5515
UNII 32HRV3E3D5
Synonyms Griseofulvin | Grisefuline | Gris-PEG | Gris PEG | GrisPEG | Grisactin | Fulvicin-U-F | Fulvicin U F | FulvicinUF | Grifulvin V
Chemical Information
Molecular Formula C17H17ClO6
CAS Registry Number 126-07-8
SMILES CC1CC(=O)C=C(C12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Asthenia08.01.01.001--Not Available
Coagulopathy01.01.02.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Dyspepsia07.01.02.001--
Eczema23.03.04.006--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hyperbilirubinaemia09.01.01.003; 01.06.04.003; 14.11.01.010--Not Available
Hypersensitivity10.01.03.003--
Insomnia19.02.01.002; 17.15.03.002--
Leukopenia01.02.02.001--Not Available
Nausea07.01.07.001--
Nephrotic syndrome20.05.01.002--
Neuropathy peripheral17.09.03.003--Not Available
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Photosensitivity reaction23.03.09.003--
Proteinuria20.02.01.011--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene